Quantification of amlodipine in dried blood spot samples by high performance liquid chromatography tandem mass spectrometry

Chen, Gaoyun; Jirjees, Feras; Bawab, Abdel Qader Al; McElnay, James

doi:10.1016/j.jchromb.2017.11.018

Cited by 22 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the higher drug concentrations in whole blood have been attributed to strong adhesion to red blood cells. 36,37 It is unclear whether these findings are related to the outcomes of the Bland-Altman analyses.…”

Section: Clinical Validationmentioning

confidence: 99%

Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites

Peeters¹,

Feyz

Hameli³

et al. 2020

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Background: Drug nonadherence is one of the major challenges faced by resistant hypertension patients, and identification of this problem is needed for optimizing pharmacotherapy. Dried blood spot (DBS) sampling is a minimally invasive method designed to detect and determine the degree of nonadherence. In this study, a DBS method for qualifying 8 antihypertensive drugs (AHDs) and 4 active metabolites was developed and validated using ultra highperformance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Method: The DBS assay was validated analytically and clinically, in accordance with FDA requirements. Analytical validation was accomplished using UHPLC-MS/MS. For clinical validation, paired peak and trough levels of DBS and plasma samples were simultaneously collected and comparatively analyzed using Deming regression and Bland-Altman analyses. All concentrations below the set lower limit were excluded. Deming regression analysis was used to predict comparison bias between the collected plasma and DBS samples, with DBS concentrations corrected accordingly. Results: The UHPLC-MS/MS method for simultaneously measuring 8 AHDs and their metabolites in DBS, was successfully validated. With Deming regression no bias was observed in N = 1; constant bias was seen in N = 6 and proportional bias in N = 11 of the AHDs and metabolites. After correction for bias, only one metabolite (canrenone) met the 20% acceptance limit for quantification, after Bland-Altman analyses. In addition, amlodipine, valsartan, and [enalaprilate] met the 25% acceptance limit. Conclusions: A novel DBS assay for simultaneously qualifying and quantifying 8 AHDs and their metabolites, has been successfully developed and validated. The DBS assay is therefore a suitable method to detect drug nonadherence. However, with the exception of canrenone, the interchangeable use of plasma and DBS sampling to interpret drug quantities should be avoided.

show abstract

Section: Clinical Validationmentioning

confidence: 99%

Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites

Peeters¹,

Feyz

Hameli³

et al. 2020

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…Area bias was the single and most influencing component contributing to overall assay bias of almost ± 40% at tested HCT levels of 30 and 60% relative to the HCT level of 45% at sub-spot sampling, whereas the effect was negligible at whole-spot sampling (Figure 4). In agreement with cortisol, other compounds such as amlodipine, midazolam, and naproxen analyzed in DBS were also shown to be independent of HCT variations [2,8].…”

Section: Hematocrit Effectmentioning

confidence: 54%

Fluispotter, a novel automated and wearable device for accurate volume serial dried blood spot sampling

Adhikari

Rohde²,

Velschow³

et al. 2020

Bioanalysis

View full text Add to dashboard Cite

Aim: A novel automated serial dried blood spot (DBS) sampler, ‘Fluispotter’, was tested for its sampling performance. Materials & methods: An LC–MS/MS method was developed for the analysis of cortisol in DBS samples serially spotted by Fluispotter. The cortisol concentrations in 148 paired DBS and plasma samples were compared across a hematocrit (HCT) range of 22–55%. Results: The interassay accuracy and precision were <10%. Overall assay bias was negligible across the HCTs tested when analyzing the whole-spot DBS samples. The accuracy and precision of the blood volume in 10 μl DBS samples spotted by Fluispotters and micropipettes were within 3%. Deming regression and Bland-Altman analysis showed a good agreement of DBS-predicted and measured plasma cortisol. Conclusion: The Fluispotter performed serial sampling with high accuracy and precision of the sample blood volume.

show abstract

“…FPB consists of whole blood were total drug levels are measured, whereas plasma measurements do not include intracellular drug levels [46]. Since some drugs can largely distribute into red blood cells, considering the different matrices is important [47]. Yet, specific reference ranges are more important in the context of therapeutic drug monitoring as in the context of adherence monitoring.…”

Section: Proof Of Conceptmentioning

confidence: 99%

Closing the gap — development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugs

et al. 2022

View full text Add to dashboard Cite

Volumetric absorptive microsampling (VAMS), an emerging microsampling technique, is a promising tool for adherence monitoring. This study focused on development of an analytical methodology to improve VAMS-based strategies for adherence assessment by analyzing angiotensin-converting-enzyme (ACE) inhibitors, loop diuretics, a potassium-sparing diuretic, and a thiazide diuretic. Development included sample preparation, chromatographic conditions, mass spectrometry settings, validation, and demonstrating proof of concept. Quantification of analytes, by name furosemide, hydrochlorothiazide, lisinopril, torasemide, and the active metabolites, canrenone, enalaprilat, and ramiprilat in finger prick blood (FPB), was validated based on international guidelines. Selectivity, carryover, and within/between-run accuracy and precision were in accordance with the recommendations. The matrix effect was evaluated at three different hematocrit levels (HT: 20%, 40%, 60%) and the coefficients of variation did not exceed 15%. Dilution integrity (1:10 and 1:20) was given for all analytes except lisinopril, yet for lisinopril, the therapeutic range was already covered by the calibration range. Long-term stability in VAMS tips was tested for 2 weeks at 24 °C in the dark and revealed no degradation of analytes. The proof of concept was performed by analyzing 35 intakes of ACE-inhibitors and diuretics in 18 VAMS and matched plasma samples. Hereby, determined concentration in FPB and plasma cannot be used interchangeably, and thus specific reference ranges for whole blood must be established. Nevertheless, the VAMS-based strategy was shown to be suitable for assessing adherence of all classes of antihypertensive drugs used in the guidelines to manage hypertension. Graphical abstract

show abstract

Quantification of amlodipine in dried blood spot samples by high performance liquid chromatography tandem mass spectrometry

Cited by 22 publications

References 30 publications

Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites

Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites

Fluispotter, a novel automated and wearable device for accurate volume serial dried blood spot sampling

Closing the gap — development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugs

Contact Info

Product

Resources

About